PATENT CLAIM ANALYSIS

Application Number: 15924039
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "001100"]

Abstract:
A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).

Claim (Index 5):
The method of  claim 1 , wherein the ADT agent is selected from the group consisting of leuprolide, goserelin, triptorelin, histrelin, degarelix, cyproterone acetate, megestrol acetate, chlormadinone acetate, medroxyprogesterone acetate, spironolactone, oxendolone, flutamide, bicalutamide, nilutamide, topilutamide, enzalutamide, apalutamide, darolutamide, and combinations thereof.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 90.0
- Lexical Diversity: 1.3125
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12920088', '14115217', '13447825', '14412235', '15331777']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8047277871129459
- 35 USC 102 Novelty (BERT): 0.5260686227947572
- Combined Prediction Score: 0.7768618706811271
- Mean Citation Score: 297.153702
- Max Citation Score: 347.8857
- Similarity Product: 272.8386985455394

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test